DMP Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Dermapharm Holding (ETR: DMP)
›
Dermapharm Holding (ETR: DMP) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 3,503 employees.
The shares were at 33.45 EUR on 19 November 2026, down 3.7% over 52 weeks. Its 52-week range is 33.10 EUR to 51.90 EUR: the price is 35.5% below the high and 1.1% above the low.
At a market capitalisation of 1.66B EUR, it trades at 13.3 times trailing earnings and 11.3 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 46% for DMP. It pays a dividend yielding 2.51% (it pays out 35% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Dermapharm Holding reports return on equity of 19.1%, an operating margin of 19.9% and revenue down 0.5% year over year.
Its debt exceeds its cash by 1.03B EUR, a debt-to-equity ratio of 1.52. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 51.00 EUR is 52.5% above the current price. The next earnings report is expected on 25 March 2027.